201 related articles for article (PubMed ID: 36259470)
1. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
[TBL] [Abstract][Full Text] [Related]
2. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
Balakirski G; Alkhateeb A; Merk HF; Leverkus M; Megahed M
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1778-1782. PubMed ID: 27357866
[TBL] [Abstract][Full Text] [Related]
4. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
5. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
7. Research progress of omalizumab in the treatment of bullous pemphigoid.
Ling X; Shou X; Lou Y; Ling J; Zhang M; Yu T; Gu W
J Dermatol; 2023 May; 50(5):575-587. PubMed ID: 36971190
[TBL] [Abstract][Full Text] [Related]
8. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
10. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
Ujiie H
J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
[TBL] [Abstract][Full Text] [Related]
11. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
Front Immunol; 2021; 12():569287. PubMed ID: 33841390
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
14. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
[TBL] [Abstract][Full Text] [Related]
15. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
16. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
17. Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab.
Sarrazin M; Jouen F; Duvert-Lehembre S
Ann Dermatol Venereol; 2021 Mar; 148(1):60-62. PubMed ID: 33478824
[No Abstract] [Full Text] [Related]
18. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
van Beek N; Schulze FS; Zillikens D; Schmidt E
Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
[TBL] [Abstract][Full Text] [Related]
19. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption.
Herrero-González JE; Sitaru C; Klinker E; Bröcker EB; Zillikens D
Clin Exp Dermatol; 2005 Sep; 30(5):519-22. PubMed ID: 16045683
[TBL] [Abstract][Full Text] [Related]
20. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
